サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：一過性脳虚血発作の世界市場：予測（2022年～2028年）
市場調査レポート
商品コード
1123331

一過性脳虚血発作の世界市場：予測（2022年～2028年）

Global Transient Ischemic Attack Market Research and Forecast, 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 150 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
一過性脳虚血発作の世界市場：予測（2022年～2028年）
出版日: 2022年08月05日
発行: Orion Market Research
ページ情報: 英文 150 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の一過性脳虚血発作の市場規模は、予測期間（2022年～2028年）中に6.1%のCAGRで成長すると予想されています。ライフスタイルや食習慣の変化、人口増加による神経疾患の蔓延、有利な償還政策は、一過性脳虚血発作市場の成長を促進しています。しかし、治療へのコスト高は、市場の成長を妨げています。

当レポートでは、世界の一過性脳虚血発作市場について調査分析し、市場概要、競合情勢、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポート概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • 主要戦略分析
  • COVID-19が主要企業に与える影響

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界の一過性脳虚血発作市場：診断別
    • 頸動脈超音波検査
    • CTスキャンとCT血管造影スキャン
    • MRIスキャンとMR血管造影
    • 心エコー検査
    • 心電図
    • その他
  • 世界の一過性脳虚血発作市場：治療別
    • 投薬
    • 手術
    • 血管形成術
  • 世界の一過性脳虚血発作市場：エンドユーザー別
    • 病院とクリニック
    • 研究機関
    • 診断センター

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第7章 企業プロファイル

  • Abbott
  • Acticor Biotech SAS
  • AstraZeneca
  • Bayer AG
  • Boston Scientific Corp.
  • Cardinal Health.
  • DAIICHI SANKYO CO. LTD.
  • electroCore, Inc.
  • Lilly
  • General Electric
  • LivaNova PLC
  • Medtronic
  • Merck KgaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Siemens Healthcare Pvt. Ltd.
  • Stryker
  • Terumo Corp.
  • Zocere, Inc.
図表

LIST OF TABLES

  • 1. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET BY DIAGNOSIS, 2020-2027($ MILLION)
  • 3. GLOBAL CAROTID ULTRASONOGRAPHY MARKET BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL CT SCAN AND CT ANGIOGRAPHY SCAN MARKET BY REGION, 2020-2027($ MILLION)
  • 5. GLOBAL MRI SCAN AND MR ANGIOGRAPHY MARKET BY REGION, 2020-2027($ MILLION)
  • 6. GLOBAL ECHOCARDIOGRAPHY MARKET BY REGION, 2020-2027($ MILLION)
  • 7. GLOBAL ELECTROCARDIOGRAM MARKET BY REGION, 2020-2027($ MILLION)
  • 8. GLOBAL OTHER MARKET BY REGION, 2020-2027($ MILLION)
  • 9. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020-2027($ MILLION)
  • 10. GLOBAL MEDICATION MARKET BY REGION, 2020-2027($ MILLION)
  • 11. GLOBAL SURGERY BY REGION, 2020-2027($ MILLION)
  • 12. GLOBAL ANGIOPLASTY BY REGION, 2020-2027($ MILLION)
  • 13. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET BY END-USERS, 2020-2027($ MILLION)
  • 14. GLOBAL HOSPITAL & CLINICS MARKET BY REGION, 2020-2027($ MILLION)
  • 15. GLOBAL RESEARCH INSTITUTES MARKET BY REGION, 2020-2027($ MILLION)
  • 16. GLOBAL DIAGNOSTIC CENTERS MARKET BY REGION, 2020-2027($ MILLION)
  • 17. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027($ MILLION)
  • 18. NORTH AMERICAN TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 19. NORTH AMERICAN TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 20. NORTH AMERICAN TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 21. NORTH AMERICAN TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027($ MILLION)
  • 22. EUROPEAN TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 23. EUROPEAN TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 24. EUROPEAN TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 25. EUROPEAN TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027($ MILLION)
  • 26. ASIA-PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 27. ASIA-PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 28. ASIA-PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 29. ASIA-PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027($ MILLION)
  • 30. REST OF WORLD TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 31. REST OF WORLD TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 32. REST OF WORLD TRANSIENT ISCHEMIC ATTACK MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL TRANSIENT ISCHEMIC ATTACK SHARE BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL TRANSIENT ISCHEMIC ATTACK, 2021-2027 (%)
  • 1. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 2. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
  • 3. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET SHARE BY END-USER, 2020 VS 2027 (%)
  • 4. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. GLOBAL CAROTID ULTRASONOGRAPHY MARKET BY REGION, 2020 VS 2027 (%)
  • 6. GLOBAL CT SCAN AND CT ANGIOGRAPHY SCAN MARKET BY REGION, 2020 VS 2027 (%)
  • 7. GLOBAL MRI SCAN AND MR ANGIOGRAPHY MARKET BY REGION, 2020 VS 2027 (%)
  • 8. GLOBAL ECHOCARDIOGRAPHY MARKET BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL ELECTROCARDIOGRAM MARKET BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL OTHER MARKET BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL MEDICATION MARKET BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL SURGERY MARKET BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL ANGIOPLASTY MARKET BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL HOSPITAL & CLINICS MARKET BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL RESEARCH INSTITUTES MARKET BY REGION, 2020 VS 2027 (%)
  • 16. GLOBAL DIAGNOSTIC CENTERS MARKET BY REGION, 2020 VS 2027 (%)
  • 17. US TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 18. CANADA TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 19. UK TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 20. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 21. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. ITALY TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. REST OF EUROPE TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. INDIA TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. CHINA TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. JAPAN TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. SOUTH KOREA TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. REST OF ASIA-PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. REST OF THE WORLD TRANSIENT ISCHEMIC ATTACK MARKET SIZE, 2020-2027 ($ MILLION)
目次
Product Code: OMR2019529

Global Transient Ischemic Attack Market Research By Diagnosis (Carotid Ultrasonography, CT Scan and CT Angiography Scan, MRI Scan and MR Angiography, Echocardiography, Electrocardiogram and Other), By Treatment (Medication, Surgery, and Angioplasty), and By End-User (Hospital & Clinics, Research Institutes, and Diagnostic Centers) Forecast 2021-2027

The global transient ischemic attack market is growing at a considerable CAGR of 6.1% during the forecast period. Changing lifestyle and eating habits is one of the prime factors affecting and driving the market. The increasing pervasiveness of neurological disorder among the population and reimbursement policies that are favorable is also estimated to be the prime factors that are contributing significantly towards the growth of the market. However, the high-cost involvement in treatment and lack of awareness with regards to diagnosis along with treatment of transient ischemic attack is one of the major factors constraints that are hindering the growth of the global transient ischemic attack market across the globe.

However, rising investments in R&D by government organizations along with advancement in technology in diagnostic tools are some of the key factors that are creating opportunities for the market. New product launches and collaboration in the market are likely to drive the growth of the global transient ischemic attack market. For instance, in October 2020, Acticor Biotech SAS which is one of the clinical-stage biotechnology companies had set forth the completion of its ACTIMIS dose-escalation phase first. This was done for patients suffering from acute ischemic stroke and 60 patients enrolled from 6 European countries that include France, Belgium, and Germany among others.

Impact of COVID-19 on the Global Transient Ischemic Attack Market

The global transient ischemic attack is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies has disrupted manufacturing and transportation. However, the proper treatment was been given by physicians to patients suffering from a mini-stroke and cardiovascular diseases.

Segmental Outlook

The market is segmented based on diagnosis, treatment, end-users. Based on the diagnosis, the market is segmented into carotid ultrasonography, CT scan and CT angiography scan, MRI scan and MR angiography, echocardiography, electrocardiogram and other. By treatment, the market is segmented into medication, surgery and angioplasty. Further, by end-users, market is segmented hospital & clinics, research institutes and diagnostic centers.

Global Transient Ischemic Attack Market Share by Diagnosis Method 2020 (%)

Global Transient Ischemic Attack Market Share by Diagnosis Method

Based on the diagnosis method, MRI scan and MR angiography is important methods in order to manage the diagnosis-related with the mini-stroke. Through this MRI scan and MR angiography, information can be easily received with regards to stroke as it offers quality imaging. Therefore, it is likely to drive the growth of the transient ischemic attack market.

Regional Outlooks

The global transient ischemic attack market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global transient ischemic attack market. Some factors that are boosting the market growth in North America are the increasing pervasiveness of cardiovascular diseases along with the presence of the leading players in the market. Additionally, increasing investment in health care expenditure in the region along with technology advancement is boosting the market in this region. Moreover, in Europe, increasing awareness with regards to treatment and diagnosis of minor stroke is one of the prime factors involved in the growth of the market in the region.

Global Transient Ischemic Attack Market, by Region 2021-2027

Global Transient Ischemic Attack Market, by Region

Asia-Pacific will have Considerable Growth in the Global Transient Ischemic Attack Market

Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing tobacco and alcohol along with rising changes in lifestyle in emerging economies of the region are likely to drive the growth of the regional market. Further, due to rising health care expenditure along with the rising pervasiveness of cardiac disorders and change in dietary habits in India, China and South Korea are also some of the factors that are affecting and impacting the growth in this market.

Market Player Outlook

Key players of the global transient ischemic attack market are Abbott, Cardinal Health, electroCore, Inc., Medtronic, and Siemens Healthcare Pvt. Ltd., among others. To survive in the market, these players adopt different marketing strategies such as product launches and collaboration. For instance, in July 2020, AstraZeneca had set forth that US Food and Drug Administration (FDA) had given acceptance to its supplemental New Drug Application (sNDA) and for Brilinta (ticagrelor). Brilinta got a priority review for patients who had experienced an acute ischemic stroke or transient ischemic attack (TIA) as it decreases the subsequent.

In December 2020, DAIICHI SANKYO CO. LTD. had announced that it had filled in Japan an application regarding the Antiplatelet Agent, Prasugrel Hydrochloride in order to elaborate for preventing of recurrence of ischemic stroke on the basis of its phase 3 study.

In April 2019, Medtronic had introduced Solitaire X Revascularization device in the US. This is considered to be the first device to be used in patients in order to do treatment of acute ischemic stroke. Through this device, it had supported every physician in order to give proper treatment to patients for effective recovery from stroke in the industry.

In July 2019, Medtronic had signed an agreement with one of the artificial intelligence (AI) stroke care companies name Viz.ai. Through this agreement, the company will look forward to provide proper information and new products related to medical devices and digital health along with complementing the existing ones.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global transient ischemic attack market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Transient Ischemic Attack Industry
  • Recovery Scenario of Global Transient Ischemic Attack Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Transient Ischemic Attack Market by Diagnosis
    • 5.1.1. Carotid Ultrasonography
    • 5.1.2. CT Scan and CT Angiography Scan
    • 5.1.3. MRI Scan and MR Angiography
    • 5.1.4. Echocardiography
    • 5.1.5. Electrocardiogram
    • 5.1.6. Other
  • 5.2. Global Transient Ischemic Attack Market by Treatment
    • 5.2.1. Medication
    • 5.2.2. Surgery
    • 5.2.3. Angioplasty
  • 5.3. Global Transient Ischemic Attack Market by End-Users
    • 5.3.1. Hospital & Clinics
    • 5.3.2. Research Institutes
    • 5.3.3. Diagnostic Centers

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott
  • 7.2. Acticor Biotech SAS
  • 7.3. AstraZeneca
  • 7.4. Bayer AG
  • 7.5. Boston Scientific Corp.
  • 7.6. Cardinal Health.
  • 7.7. DAIICHI SANKYO CO. LTD.
  • 7.8. electroCore, Inc.
  • 7.9. Lilly
  • 7.10. General Electric
  • 7.11. LivaNova PLC
  • 7.12. Medtronic
  • 7.13. Merck KgaA
  • 7.14. Novartis AG
  • 7.15. Novo Nordisk A/S
  • 7.16. Pfizer Inc.
  • 7.17. Sanofi
  • 7.18. Siemens Healthcare Pvt. Ltd.
  • 7.19. Stryker
  • 7.20. Terumo Corp.
  • 7.21. Zocere, Inc.